The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)

Consolidated Financial Statements for the Third Quarter Ended December 31, 2020
FY2021 (April 1, 2020 - March 31, 2021) [UNAUDITED]
February 10, 2021
Takara Bio Inc.
Tokyo Stock Exchange (1st section)4974
https://www.takara-bio.co.jp
Koichi Nakao, President
Takuya Kakemi, General Manager of Corporate
Management Division, Executive Officer
Tel. (077) 565-6970
February 12, 2021

Company name:
Stock exchange listings:
Code number:
URL:
Company representative:
Contact:

Scheduled date of quarterly statement filing:
Scheduled date of starting delivery of dividends:－
Supplementary documents of the financial results:
Yes
Financial results information meeting:No
Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles andpractices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.
1. Results for the nine months ended December 31, 2020 (Apr. 1, 2020 – Dec. 31, 2020)(1) Consolidated operating results(Percentages indicate changes from the same period of the previous fiscal year.)Nine months ended
Dec. 31, 2020
Net sales
Operating profit
Ordinary profit
Net income (loss) attributable to owners ofparent
Net income per share (in yen)
Fully diluted net income per share (in yen)
(Note) Comprehensive income(Millions of yen)
29,549
8,791
8,919
5,726
47.56
－
4,940

Nine months ended
Dec. 31, 2019
20.3
126.6
128.9
111.4

(Millions of yen)
24,558
3,879
3,896
2,708

(5.1)
13.0
9.8
29.7

226.6

22.49
－
1,512

(14.8)(%)(%)(2) Consolidated financial position

Total assets
Net assets
Equity ratio (%)
Net assets per share (in yen)
(Reference) Equity

As of Dec. 31, 2020
(Millions of yen)

As of Mar. 31, 2020
(Millions of yen)

83,84670,56884.0
585.1270,45775,00966,591
88.7
552.2366,496

2. Dividends
Year ended
Mar. 31, 2020

Year ending
Mar. 31, 2021

Annual dividends per share in yen
Year ending
Mar. 31, 2021 (Forecast)First quarter end－－
Second quarter end
0.00
0.00
Third quarter end－－
Year end
8.00
Annual8.00(Note) Revision of dividend payment forecast since the most recently announced payment forecast: Yes

14.00
14.00

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)
3. Forecast for the year ending March 31, 2021 (Apr. 1, 2020 – Mar. 31, 2021)(Percentages indicated changes from the same period of the previous fiscal year.)Year ending Mar. 31, 2021
(Millions of yen)
Net sales
45,200Operating profit
12,000Ordinary profit
12,100Net income attributable to owners of the parent
7,800
Net income per share (in yen)
64.78
(Note) Revision of financial forecast since the most recently announced payment forecast: Yes
※

(%)
30.8
91.2
90.6
104.2

Others(1) Changes in subsidiaries during the nine months ended December 31, 2020
(Changes in specified subsidiaries resulting in change of scope) ： No
Newly included: － (Name)
Excluded: － (Name)(2) Application of special accounting methods to the consolidated quarterly financial statements： No(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement
1) Changes based on revisions of accounting standard： No
2) Changes other than ones based on revisions of accounting standard： No
3) Changes in accounting estimates： No4) Restatement： No(4) Number of outstanding shares (Common stock)1) Number of outstanding shares at year end (Treasury stocks are included)
120,415,600
As of December 31, 2020
As of March 31, 2020
120,415,600
2) Number of treasury stocks at year end－
As of December 31, 2020－
As of March 31, 2020
3) Average number of outstanding shares
120,415,600
As of December 31, 2020
120,415,600
As of December 31, 2019

※ These financial statements are not subject to auditing.
※ Comment regarding appropriate use of earnings forecasts and other special notes
Forward-looking statements contained in this document are determined by the Takara Bio Company based on information
currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due
to changes in conditions that occur in the future. For information regarding the above, please refer to 1. Qualitative Information
for the nine months ended December 31, 2020 (4) Qualitative Information Regarding Consolidated Forecasts, on page 2 of theattached document.

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)

Contents of the attached document
1. Qualitative Information for the nine months ended December 31, 2020…………………...........…………………………...
(1) Overview of Financial Results……………………………………………………….………….………….…………......
(2) Overview of Financial Position………………………………………………...…………………………...……..............
(3) Overview of Cash Flows…………………………………………………………….…………………………….……....
(4) Qualitative Information Regarding Consolidated Forecasts………………………………………………………………
2. Consolidated Quarterly Financial Statements and Primary Notes…………………………………………………………….
(1) Consolidated Quarterly Balance Sheets…………………………………………………………………………………...
(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income……..
(Consolidated Quarterly Statements of Profit or Loss)(For the nine months ended December 31, 2020) ……………………………………………………………………..
(Consolidated Quarterly Statements of Comprehensive Income)(For the nine months ended December 31, 2020) ……………………………………………………………………..
(3) Consolidated Quarterly Statements of Cash Flows………………………………………………………………………..
(4) Notes to Consolidated Quarterly Financial Statements……………………………………………………………………
(Notes on Premise of Going Concern) …………………………………………………………………………………..
(Notes in case of Changes in Marked Amount of Shareholders’ Equity) ……………………………………………….
(Additional Information)………………………………………………..…………..…………..…………..…………....
(Segment Information)……………………………………………………………………………..……………….……
3. Supplementary Information …………………………………………………………………………………………………..
(1) Trends in Key Management Indicators……………………………………………………………………………………
(2) Comparative Consolidated Statement of Profit or Loss …………………………………………………………………..
(3) Comparative Statement of Profit Relating to Consolidated Earnings Forecast…………………………………………...

- 1 -

2
2
2
2
2
3
3
5
5
6
7
8
8
8
8
8
9
9
10
11

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)
1. Qualitative Information for the nine months ended December 31, 2020
(1) Overview of Financial Results
In the fiscal year under review, ended December 31, 2020, the global economy has continued to be uncertain due to the influenceof the new Coronavirus disease (COVID-19) pandemic, the trade friction issue in the US and China, and Brexit, etc.
Against these circumstances, under our corporate philosophy of “Contributing to the health of humankind through thedevelopment of revolutionary biotechnologies such as gene therapy”, Takara Bio (the Company) is promoting the development of
bio-drug discovery platform technologies through the businesses of research reagents and scientific instruments and CDMO
business, aiming to become a drug discovery company and continuously creates new modalities in line with “Long-Term
Management Plan FY2026” and “Medium-Term Management Plan FY2023”. Amid the worldwide expansion of COVID-19, theCompany prioritized the stable supply of PCR testing-related products, and the establishment of a manufacturing system forregenerative medicine products including vaccine, for which social demands are high.
Overall net sales in the third quarter of the current fiscal year, although sales of Gene Therapy decreased year on year, sales ofresearch reagents and contract services increased year on year. In addition, sales of PCR testing-related products, including in vitro
diagnostics for detecting the new coronavirus launched in November, increased. As a result, net sales increased 20.3% to ¥29,549
million. Cost of sales decreased 15.0% year on year to ¥8,297 million due to the change of sales composition by item and others,
and an increase in production utilization rates, and gross profit increased 43.7% year on year to ¥21,251 million. Selling, generaland administrative (SG&A) expenses increased 14.2% year on year to ¥12,460 million due to the increase in R&D expenses, etc.,
and the Company recorded operating profit up 126.6% year on year to ¥8,791 million.
Accompanied with the increase in operating profit, ordinary profit increased 128.9% to ¥8,919 million, profit before income taxes
and others increased 115.3% year on year to ¥8,359 million, and net income attributable to owners of parent increased 111.4% year
on year to ¥5,726 million.
Segment information has been omitted because the reportable segments were changed to a single segment from the three months
ended June 30, 2020. For details, please refer to “2. Consolidated Quarterly Financial Statements and Primary Notes (Segment
Information)”.
Sales of in vitro diagnostics sold from the third quarter of current fiscal year has been classified as research reagents.
(2) Overview of Financial Position
In the third quarter of the current fiscal year, total assets were ¥83,846 million, an increase of ¥8,836 million compared with that at
the end of the previous fiscal year. This primarily resulted from an increase in non-current assets by ¥5,354 million based on theacquisition of land and building for the new facility of Takara Bio USA, Inc. and the Company’s manufacturing facility, etc.
Total liabilities were ¥13,277 million, an increase of ¥4,859 million compared with that at the end of the previous fiscal year.
This primarily resulted from increases of ¥3,349 million in others for current liabilities and ¥1,062 million in accrued income taxes.
Total net assets stood at ¥70,568 million, an increase of ¥3,976 million compared with that at the end of the previous fiscal year.
The main factor was an increase of ¥4,763 million in retained earnings and a decrease of ¥827 million in foreign currency translation
adjustment due to the appreciation of the yen.
(3) Overview of Cash FlowsNet cash provided by operating activities was ¥7,978 million, up by ¥3,290 million compared with the same period of the previous
fiscal year. This was mainly due to cash inflow of profit before income taxes and others of ¥8,359 million, depreciation andamortization of ¥2,421 million, ¥1,567 million from an increase in current liabilities, and cash outflow of an increase of ¥2,242
million in trade receivables and ¥2,003 million from an increase in inventories.
Net cash provided by investing activities was ¥1,675 million, a decrease of ¥905 million compared with the same period of theprevious fiscal year. This was primarily due to ¥6,994 million in payments for purchase of property, plant and equipment andintangible assets, ¥2,082 million in subsidies received, and ¥2,000 million in proceeds from sales and redemption of securities.
Net cash used in financing activities was ¥1,068 million, an increase of ¥138 million compared with the same period of theprevious fiscal year. This was primarily because of cash dividends paid of ¥962 million.
As a result of the above, balance of cash and cash equivalents at the end of third quarter of the current fiscal year, including theeffect of exchange rate change on cash and cash equivalents, stood at ¥19,467 million, up by ¥5,004 million from the previous
fiscal year-end.
(4) Qualitative Information Regarding Consolidated Forecasts
The Company has revised the financial forecast and the dividend forecast disclosed on November 10, 2020. For details, refer to“Notice Regarding Forecast Revisions of Financial results and Dividend (Dividend Increase)” disclosed on February 10, 2021.
For comparison between revised forecast for consolidated results, previous period results, and previous forecast, refer to“Comparative Statement of Profit Relating to Consolidated Earnings Forecasts” on page 11.

- 2 -The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)
2. Consolidated Quarterly Financial Statements and Primary Notes(1) Consolidated Quarterly Balance Sheets(Millions of yen)
As of Mar. 31, 2020
AssetsCurrent assets
Cash and deposits
Notes and accounts receivable-tradeMarketable securities
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures
Accumulated depreciation
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation
Machinery, equipment and vehicles, net
Tools, furniture and fixtures
Accumulated depreciation
Tools, furniture and fixtures, net
LandConstruction in progress
Others
Accumulated depreciation
Others, net
Total Property, plant and equipment
Intangible assets
Goodwill
Other
Total intangible assets
Investments and other assets
Investments and other assets
Total investments and other assets
Total non-current assets
Total assets- 3 -As of Dec. 31, 2020

18,266
9,102
2,000
4,511
1,208
1,874
1,479
(56)
38,387

21,856
11,283
－
4,994
1,748
2,656
778
(54)
43,263

16,478(5,630)10,847
6,705(3,353)
3,352
7,912(5,217)
2,694
5,724
85
1,635
(126)
1,509
24,213

15,495(4,933)
10,562
6,977(3,665)3,311
7,857(5,284)
2,573
8,195
3,521
1,639
(235)
1,404
29,568

7,006
4,348
11,355

6,406
3,376
9,782

1,053
1,053
36,62275,0091,231
1,231
40,582
83,846

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)(Millions of yen)
As of Dec. 31, 2020

As of Mar. 31, 2020
Liabilities
Current liabilities
Notes and accounts payable-trade
Accrued income taxes
Provision
Other
Total current liabilities
Non-current liabilities
Retirement benefit liabilities
Other
Total non-current liabilities
Total liabilities
Net assets
Shareholders’ equity
Share capital
Capital surplus
Retained earnings
Total shareholders' equity
Accumulated other comprehensive income
Foreign currency translation adjustment
Remeasurements of retirement benefit
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets

- 4 -

1,027
683
557
3,978
6,248

1,464
1,746
622
7,328
11,161

783
1,386
2,169
8,418

789
1,326
2,115
13,277

14,96532,89318,501
66,36014,96532,89323,265
71,124

436
(300)
135
95
66,59175,009

(391)
(275)
(667)
111
70,56883,846

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income(Consolidated Quarterly Statements of Profit or Loss)(For the nine months ended December 31, 2020)(Millions of yen)
Nine months ended
Dec. 31, 2020

Nine months ended
Dec. 31, 2019
Net sales
Cost of sales
Gross profit
SG&A expenses
Employees' salaries and bonuses
Retirement benefit expenses
R&D expenses
Provision for doubtful accounts and bonuses
Other
Total SG&A expenses
Operating profit
Non-operating profit
Interest income
Foreign exchange gains
Rent income from real estate
Other
Total non-operating profit
Non-operating expenses
Interest expenses
Foreign exchange loss
Rent expenses on real estate
Expenses of inactive non-current assets
Other
Total non-operating expenses
Ordinary profit
Extraordinary profit
Gain on sale of fixed assets
National subsidies
Total extraordinary profit
Extraordinary losses
Loss on sale and retirement of fixed assets
Loss on business liquidation
Loss on tax purpose reduction entry of non-current
assetsLoss on sale of investment securities
Other
Total extraordinary losses
Profit before income taxes and others
Income taxes-current
Income taxes-deferred
Total income taxes
Net income
Net income attributable to non-controlling interest
Net income attributable to owners of the parent- 5 -24,5589,767
14,791

29,5498,297
21,251

3,045
128
2,812
224
4,701
10,911
3,879

3,313
145
3,656
305
5,039
12,460
8,791

98
－
82
32
212

85
3
93
23
205

2
153
26
4
8
195
3,896

18
－
38
16
2
77
8,919

0
－
0

1
35
36

11
－

49
462

－

35

2
－
13
3,883
935
229
1,165
2,717
8
2,708

－
49
596
8,359
2,693
(83)
2,610
5,749
22
5,726

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)(Consolidated Quarterly Statements of Comprehensive Income)(For the nine months ended December 31, 2020)(Millions of yen)
Nine months ended
Dec. 31, 2020

Nine months ended
Dec. 31, 2019
Net income
Other comprehensive income
Foreign currency translation adjustment
Remeasurements of retirement benefit
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to:
Owners of the parent
Non-controlling interest

- 6 -

2,717

5,749

(1,222)18(1,204)
1,512

(834)
25
(809)
4,940

1,506
5

4,923
16

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)(3) Consolidated Quarterly Statements of Cash Flows(Millions of yen)

Nine months ended
Dec. 31, 2019
Net cash provided by (used in) operating activities
Profit before income taxes and others
Depreciation and amortization
Depreciation and amortization on other
Amortization of goodwill
Increase (decrease) in allowance for doubtful accounts
Increase (decrease) in other provision
Increase (decrease) in retirement benefit liabilities
Interest income
Interest expenses
Loss (gain) on sale and retirement of fixed assets
Loss on business liquidation
Decrease (increase) in trade receivables
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payable-trade
Increase (decrease) in other current liabilities
Other
SubtotalInterest and dividend income received
Income expenses paid
Income taxes paid
Net cash provided by (used in) operating activities
Net cash provided by (used in) investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of marketable securities
Proceeds from sale and redemption of marketablesecurities
Purchase of property, plant and equipment andintangible assets
Proceeds from sales of property, plant and equipment
and intangible assets
Purchase of other depreciable assets
Subsidies received
Other
Net cash provided by (used in) investing activities
Net cash provided by (used in) financing activities
Dividends paid
Repayments of lease obligations
Net cash provided by (used in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period- 7 -Nine months ended
Dec. 31, 2020

3,883
2,102
89
372
3
(133)
30
(98)
2
11
－
1,686
(1,201)(382)(1,039)
233
5,560
98
(2)
(968)
4,688

8,359
2,421
61
367
(1)
68
5
(85)
18
48
462
(2,242)(2,003)
450
1,567
(26)
9,473
86
(18)
(1,563)
7,978(4,964)5,352(2,000)(2,038)
3,422
－

2,000

2,000

(3,011)(6,994)

99

14

(57)
－
(0)
(2,581)

(159)
2,082
(2)
(1,675)

(841)
(88)
(929)
(399)
777
9,464
10,241(962)(105)(1,068)(230)
5,004
14,462
19,467

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)(4) Notes to Consolidated Quarterly Financial Statements(Notes on Premise of Going Concern)
No items to report.
(Notes in case of Changes in Marked Amount of Shareholders’ Equity)
No items to report(Additional Information)(Accounting Estimates for the COVID-19 Pandemic)
At the end of the previous fiscal year, it was assumed that the impact of the COVID-19 on our group would recover gradually
to be nearly disappeared in the second half of FY2021. However, based on information available at the time of preparation of
the consolidated financial statements for the third quarter of the fiscal year under review, the Company revised the assumptionthat the impact will continue for a certain period of FY2022, although it varies by region. The Company made estimates andjudgments regarding the impairment loss of goodwill and the recoverability of deferred tax assets at the end of the third quarterof the fiscal year under review based on revised assumptions, but no indicators of impairment have been identified for goodwill,
and the Company has determined that no additional valuation allowance is required for the recoverability of deferred tax funds.
Due to the high degree of uncertainty associated with the impact of the COVID-19, any change in the above assumptions
could have an impact on the Group's financial condition and results of operations.
(Segment Information)【Segment Information】
I Equivalent period of previous fiscal year (From Apr. 1, 2019 to Dec. 31, 2019)
It is described in II the nine months ended December 31, 2020 (Matters related to changes and others by reportable segment).
II Nine months ended December 31, 2020 (From Apr. 1, 2020 to Dec. 31, 2020)
This information is omitted because the Company consists of a single segment.
(Matters related to changes and others by reportable segment)
Each business division established for products and services respectively has formulated a comprehensive strategy for the
products and services it handles, including its subsidiaries, and has developed its business activities. In April 2020, however,
the Company decided to change the business structure with the aim of becoming a drug discovery company that creates newmodalities by integrating its management resources and developing platform technology for biologics discovery.
As a result of this organizational review, the Bioindustry and Gene Therapy business segments, which were previously
reported segments, have been changed to a single business segment from the first quarter of the fiscal year under review,
and as a result, the reportable segments have become a single segment.
Due to this change, segment information for the third quarter of the previous fiscal year and the third quarter of the current
fiscal year has been omitted.

- 8 -The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)
3. Supplementary Information(1) Trends in Key Management Indicators1). Cash Flow
Nine months ended
Dec. 31, 2019
Term
(Apr. 1, 2019 – Dec. 31, 2019)
Net cash provided by (used(Millions of yen)
Nine months ended
Year ended
Dec. 31, 2020
Mar. 31, 2020
(Apr. 1, 2020 - Dec. 31, 2020) (Apr. 1, 2019 - Mar. 31, 2020)

4,688

7,978

6,339

Net cash provided by (usedin) investing activities(2,581)(1,675)(212)

Net cash provided by (usedin) financing activities(929)(1,068)(946)in) operating activities

2). Net Sales by Region
Term(Millions of yen)
Nine months ended
Dec. 31, 2019

Nine months ended
Dec. 31, 2020

Year ended
Mar. 31, 2020

(Apr. 1, 2019 – Dec. 31, 2019) (Apr. 1, 2020 - Dec. 31, 2020)(Apr. 1, 2019 - Mar. 31, 2020)

Japan

9,892

12,425

U.S.

6,129

5,745

8,011

China

4,642

5,542

6,391

1,393

2,709

1,877

Europe

2,311

2,547

3,207

Other

189

578

271

24,55829,54934,565Asia excluding Japan and
China

Total

14,8043). R&D expenses by reportable segment
Disclosure is omitted because the reportable segments have been changed to a single segment from the first quarter ofthe current fiscal year.

- 9 -The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)(2) Comparative Consolidated Statement of Profit or Loss
(Rounded down to one million yen)
Nine months ended
Dec. 31, 2019
ActualNine months ended
Dec. 31, 2020
ActualYear on year
ChangeYear on year
Ratio

Research reagents
Scientific instruments
Contract services
Gene therapy

18,042
952
3,392
2,170

22,615
1,113
5,575
243

4,573
161
2,183
(1,927)125.3%
116.9%
164.3%
11.2%

Total net sales

24,55829,5494,990

120.3%

24,55829,5494,990

120.3%（Net Sales）(Operating profit and Loss)
Net sales
Cost of sales

9,767

8,297

(1,469)85.0%

Gross profits

14,791

21,2516,460

143.7%

SG&A expenses

10,911

12,4601,548

114.2%

Transportation expenses
Advertising expenses
Promotion expenses
R&D expenses
Administrative expenses, other
Enterprise taxes (external standards taxation)

332
52
434
2,812
7,060
218

545
40
489
3,656
7,453
274

212
(11)
54
843
393
55

163.9%
77.4%
112.7%
130.0%
105.6%
125.3%

Operating profit

3,879

8,791

4,911

226.6%

212

205

(6)

96.7%

(Non-operating profit and Expenses)
Non-operating profit
Non-operating expenses
Ordinary profit(Extraordinary profit & Losses)
Extraordinary profit
Extraordinary losses

195

77

(118)

39.5%

3,896

8,919

5,023

228.9%

036

357725.0%

13

596

582

4306.9%Profit before income taxes and others

3,883

8,359

4,476

215.3%

Income taxes

1,165

2,610

1,444

223.9%Net Income
Net income (loss) attributable to non-controllinginterests
Net income attributable to owners of the parent

2,717

5,749

3,031

211.6%

Depreciation and amortization(Property, plant and equipment and intangible assets)
Amortization of goodwill

8

22

13

257.3%

2,708

5,726

3,018

211.4%

2,102

2,421

318

115.1%

372

367

(5)

98.6%

※1 Net sales of research reagents include that of in vitro diagnostics, which have been sold in the third quarter of the fiscal year
under review.
※2 Net sales of “Other” in the previous fiscal year were included in “Research reagents” from the first quarter of current fiscal year,
and results for the third quarter of the previous fiscal year in this table have been reclassified to reflect this change.
※3 The disclosure of profit and loss by segment (operating profit) is omitted because the reporting segments were changed to a single
segment from the first quarter of the current fiscal year.

- 10 -

The original disclosure in Japanese was released on February 10, 2021 at 15:00 (GMT+8)(3) Comparative Statement of Profit Relating to Consolidated Earnings Forecasts（Net Sales）

Year ended
Mar. 31, 2020

Year ending
Mar. 31, 2021

Year ending
Mar. 31, 2021

ActualPrevious forecast

Current forecast(Rounded down to one million yen)Previous Previous
forecast
forecast
ChangeRatio

Year on year
ChangeYear on year
Ratio

（Net Sales）

Research reagents

24,84029,94034,0149,173

136.9%

4,073

113.6%

Scientific instruments

1,242

1,454

1,844

601

148.4%

389

126.8%

Contract services

6,186

8,539

9,087

2,901

146.9%

548

106.4%

Gene therapy

2,295

865

253

(2,042)

11.0%

(611)

29.3%

Total Net Sales

34,56540,80045,200

10,634130.8%

4,400

110.8%Net Sales

34,56540,80045,200

10,634130.8%

4,400

110.8%

Cost of sales

13,45915,42015,526

2,067

115.4%

105

100.7%

Gross profits

21,10525,37929,6738,567

140.6%

4,294

116.9%

SG&A expenses

14,83017,37917,673

2,842

119.2%

294

101.7%

Transportation expenses

492

693

725

232

147.3%

32

104.6%

Advertising expenses

73

58

57

(15)

78.4%

(1)

97.4%

(Operating profit and Loss)

Promotion expenses

579

724

726

147

125.5%

2

100.4%

R&D expenses

3,869

5,173

5,288

1,418

136.7%

115

102.2%

Administrative expenses, other
Enterprise taxes(external standards taxation)

9,511

10,39910,503992

110.4%

103

101.0%

305

329

371

66

121.8%

42

112.7%

Operating profit

6,274

8,000

12,0005,725

191.2%

4,000

150.0%

316

207

328

11

103.7%

20

106.6%(Non-operating profit and Expenses)
Non-operating profit
Non-operating expenses

243

207

228

(15)

93.7%

20

109.8%

6,347

8,100

12,1005,752

190.6%

4,000

149.4%

Extraordinary profit

0

1

76

76

16399.5%

756418.3%Extraordinary losses

Ordinary profit(Extraordinary profit & Losses)

914

679

743

(170)

81.3%

64

109.5%

Profit before income taxes andothers

5,433

7,421

11,4335,999

210.4%

4,011

154.0%

Income taxes

1,601

2,394

3,598

1,996

224.6%

1,203

150.2%Net Income

3,831

5,027

7,834

4,002

204.5%

2,807

155.9%Net income (loss) attributable tonon-controlling interests
Net income attributable toowners of the parent

11

27

34

22

292.0%

7

128.5%

3,819

5,000

7,800

3,980

204.2%

2,800

156.0%

Depreciation and amortization(Property, Plant and equipment
and intangible assets)

2,921

3,305

3,236

315

110.8%

(68)

97.9%

496

486

486

(10)

97.9%

(0)

99.9%

Amortization of goodwill※1 Net sales of research reagents include that of in vitro diagnostics, which have been sold in the third quarter of the fiscal year underreview.
※2 Net sales of “Other” in the previous fiscal year were included in “Research reagents” from the fiscal year under review, and results
for the previous fiscal year in this table have been reclassified to reflect this change.
※3 The disclosure of profit and loss by segment (operating profit) is omitted because the reporting segments were changed to a single
segment from the current consolidated fiscal year.

- 11 -